AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I drugs for Bladder Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AL-8326’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AL-8326 is under development for the treatment of advanced solid tumors including glioblastoma multiforme (GBM), small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, endometrial cancer, cervical cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, head and neck cancer, prostate cancer, kidney cancer, bladder cancer, gastrointestinal stromal tumor and cholangiocarcinoma. It is administered through oral route. The drug candidate is a multikinase inhibitor that acts by targeting Aurora B, FGFR (fibroblast growth factor receptor) and VEGFR (vascular endothelial growth factor receptor).
Advenchen Laboratories overview
Advenchen Laboratories is a pharmaceutical company that offers healthcare solutions. The company conducts pharmaceutical research and develops small molecule cancer drug discovery programs. It provides pipeline such as angiogenesis inhibitors and small molecule protein tyrosine kinases inhibitors, among others. Advenchen Laboratories provides services such as producing inhibitors for the treatment of human colon cancer, liver cancer, gastric cancer, lungs and breast cancer, among others. Advenchen Laboratories also provides customized chemical intermediate services. The company operates in China and the US. Advenchen Laboratories is headquartered in Moorpark, California, the US.
For a complete picture of AL-8326’s drug-specific PTSR and LoA scores, buy the report here.